OncoAssure is a medical diagnostics company focused on enhancing cancer management through the identification and commercialization of clinically significant biomarkers. Their primary product, the OncoAssure Prostate test, is a post-biopsy diagnostic tool that evaluates the expression of specific genes associated with prostate cancer progression. This test aims to provide a more accurate assessment of a patient's risk for aggressive prostate cancer, thereby facilitating optimal treatment decisions. By utilizing a concise panel of genes, the test can be performed in-house at hospital pathology laboratories, which not only reduces costs but also improves turnaround times for results.

The OncoAssure process integrates advanced transcriptomic analysis with mathematical modeling techniques, ensuring rigorous analytical and clinical validation of their tests. The company is committed to addressing unmet clinical needs in oncology, as evidenced by their ongoing development of additional tests for other cancer types, including cutaneous melanoma and various carcinomas. With a team that possesses extensive expertise in cancer biomarker development, OncoAssure is positioned to make significant contributions to the field of oncology diagnostics, ultimately aiming to improve patient outcomes through more personalized treatment strategies.

Ireland

OncoAssure is a medical diagnostics company that identifies, develops, and commercialises clinically important biomarkers to significantly improve cancer management and treatment. We aim to help clinicians provide the right treatment to the right patient at the right time.

OncoAssure

Company Details